Kinkini Roy, PhD

Dr. Roy is an accomplished associate director of formulation development in drug delivery at Aviceda Therapeutics, a disruptive clinical-stage biotech company in Cambridge, Massachusetts, a position she has held since 2023. With over 20 years of experience in her profession, she has made significant contributions to various industries through her innovative work and leadership. Notably, Aviceda Therapeutics specializes in designing drugs to specifically target a particular organ or region in the body. This targeted drug delivery uses glycan to create biological medicines that do not cause harm like traditional drugs.
Dr. Roy joined Lyndra Therapeutics as a principal investigator, formulation lead, and CMC lead, where she played a pivotal role in developing a slow-release drug delivery system designed to remain in the stomach for 20 days, aimed at treating mental illnesses such as schizophrenia. More recently, Dr. Roy was the scientific director for lipid nanoparticle and polymer nanoparticle-based delivery at Phosphorex LLC from 2022 to 2023.

Dr. Roy’s tenure at The Lubrizol Corporation from 2012 to 2018 was marked by her role as an innovation and new product development group leader, where she managed a team of scientists, and developed a cost-effective membrane purification system, which led to a successful business.

Dr. Roy’s academic background includes a Master of Science in biotechnology from the University of Calcutta in 2003 and a Doctor of Philosophy in polymer, organic, nanomaterial, and supramolecular chemistry in 2011. She also completed a postdoctoral fellowship in polymer science at the University of Massachusetts Amherst and received a diploma with a specialization in leadership and management from Harvard Business School.